- Home
- GALT vs PROK Comparison
GALT vs PROK Comparison
Compare GALT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- PROK
- Stock Information
- Founded
- GALT 2000
- PROK 2015
- Country
- GALT United States
- PROK United States
- Employees
- GALT N/A
- PROK N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GALT Health Care
- PROK Health Care
- Exchange
- GALT Nasdaq
- PROK Nasdaq
- Market Cap
- GALT 86.0M
- PROK 94.9M
- IPO Year
- GALT N/A
- PROK N/A
- Fundamental
- Price
- GALT $1.38
- PROK $0.72
- Analyst Decision
- GALT Hold
- PROK Buy
- Analyst Count
- GALT 1
- PROK 4
- Target Price
- GALT N/A
- PROK $5.00
- AVG Volume (30 Days)
- GALT 177.7K
- PROK 1.1M
- Earning Date
- GALT 05-19-2025
- PROK 05-16-2025
- Dividend Yield
- GALT N/A
- PROK N/A
- EPS Growth
- GALT N/A
- PROK N/A
- EPS
- GALT N/A
- PROK N/A
- Revenue
- GALT N/A
- PROK $76,000.00
- Revenue This Year
- GALT N/A
- PROK N/A
- Revenue Next Year
- GALT N/A
- PROK N/A
- P/E Ratio
- GALT N/A
- PROK N/A
- Revenue Growth
- GALT N/A
- PROK N/A
- 52 Week Low
- GALT $0.73
- PROK $0.46
- 52 Week High
- GALT $3.41
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- GALT 49.81
- PROK 42.92
- Support Level
- GALT $1.26
- PROK $0.94
- Resistance Level
- GALT $1.63
- PROK $0.77
- Average True Range (ATR)
- GALT 0.13
- PROK 0.12
- MACD
- GALT 0.02
- PROK -0.01
- Stochastic Oscillator
- GALT 37.50
- PROK 21.71
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.